Kura Oncology (NASDAQ:KURA) Insider Sells $79,485.54 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Brian Powl sold 8,891 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $79,485.54. Following the sale, the insider owned 99,676 shares of the company’s stock, valued at $891,103.44. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Kura Oncology Stock Down 1.3%

NASDAQ KURA opened at $8.85 on Wednesday. The business has a fifty day moving average price of $7.43 and a 200 day moving average price of $6.66. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. The company has a market cap of $768.15 million, a P/E ratio of -3.92 and a beta of 0.19. Kura Oncology, Inc. has a one year low of $5.41 and a one year high of $19.73.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.90). The firm had revenue of $15.29 million for the quarter, compared to analyst estimates of $64.95 million. Research analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of KURA. Tower Research Capital LLC TRC raised its holdings in Kura Oncology by 471.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after buying an additional 9,958 shares during the period. Rangeley Capital LLC purchased a new stake in shares of Kura Oncology in the 2nd quarter valued at approximately $669,000. Man Group plc raised its stake in shares of Kura Oncology by 234.7% in the 2nd quarter. Man Group plc now owns 522,388 shares of the company’s stock valued at $3,014,000 after acquiring an additional 366,324 shares during the period. EcoR1 Capital LLC lifted its holdings in shares of Kura Oncology by 59.1% in the 2nd quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock worth $24,234,000 after acquiring an additional 1,559,702 shares during the last quarter. Finally, Engineers Gate Manager LP boosted its position in shares of Kura Oncology by 8.7% during the 2nd quarter. Engineers Gate Manager LP now owns 62,564 shares of the company’s stock worth $361,000 after purchasing an additional 5,028 shares during the period.

Analysts Set New Price Targets

A number of research firms have weighed in on KURA. JMP Securities decreased their target price on shares of Kura Oncology from $28.00 to $24.00 and set a “market outperform” rating on the stock in a research note on Monday, August 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 26th. Wall Street Zen raised Kura Oncology from a “sell” rating to a “hold” rating in a research note on Sunday, August 17th. Guggenheim assumed coverage on Kura Oncology in a research note on Thursday, September 4th. They issued a “neutral” rating for the company. Finally, Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Kura Oncology in a report on Friday, June 20th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.10.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.